Clinical Research on Detecing of the Combined Survivin mRNA with Cytokeratin 19(ck19) mRNA in Peripheral Blood of Non-small Cell Lung Cancer
|School||Dalian Medical University|
|Keywords||Survivin mRNA CK19 mRNA CEA CYFRA21-1 Non-small cell lung cancer|
Objective: To detect non-small cell lung cancer (Non-small cell lung cancer, NSCLC) patients with survivin (Survivin) mRNA and cytokeratin 19 (CK19) mRNA expression; and with carcinoembryonic antigen (CEA), cytokeratin fragment antigen 21-1 (CYFRA21-1) compared Survivin mRNA United CK19 mRNA was observed in NSCLC early diagnosis, early detection of micrometastasis clinical value and significance. Methods: 55 cases collected in patients with non-small cell lung cancer, 30 cases of benign lung disease, 30 patients with human peripheral blood by reverse transcription polymerase chain reaction (RT-PCR) detection of Survivin mRNA and CK19 mRNA expression; using electrochemiluminescence immunoassay (Electro-Chemiluminescence Immunoassay, ECLI) detecting CEA, CYFRA21-1 expression, analyze them and the relationship between clinicopathological factors. Results: Survivin mRNA and CK19 mRNA in NSCLC group, the positive rate was 61.82% (34/55) and 49.09% (27/55); benign lesions positive rates were 6.67% (2/30) and 16.67% (5 / 30); healthy control group positive rate of 0%, a significant difference (P lt; 0.01). The positive expression rate and clinical TNM stage (P lt; 0.01), and gender, age, pathological histological types (P gt; 0.05). CEA, CYFRA21-1 two indicators in NSCLC group, the positive rates were 43.64% (24/55) and 34.55% (19/55), the positive expression rate and clinical TNM stage, histological type related (P lt; 0.05). Survivin mRNA and CK19 mRNA in NSCLC group combined detection sensitivity was 80.00% (44/55), specificity of 90% (54/60), the accuracy was 85.22% (98/115). CEA CYFRA21-1 combined with a sensitivity of 50.91% (28/55), specificity of 85% (51/60), the accuracy was 68.70% (79/115). Survivin mRNA and CK19 mRNA compared CEA joint detection CYFRA21-1 combined with the sensitivity and accuracy of detection of statistically significant (P lt; 0.05), specificity was no significant difference (P gt; 0.05). Conclusion: 1.Survivin mRNA compared with CK19 mRNA, CEA, CYFRA21-1 in NSCLC patients with high expression. Survivin mRNA expression in peripheral blood can be used as auxiliary diagnosis of micrometastasis NSCLC and a valuable tumor marker. 2.Survivin mRNA and CK19 mRNA joint detection sensitivity and accuracy than CEA in CYFRA21-1 increased. Survivin mRNA combined CK19 mRNA detection may help to improve the detection rate of early NSCLC and early detection of micrometastases in order to guide clinical diagnosis. 3. CEA for adenocarcinoma sensitive, CYFRA21-1 对 squamous sensitive. CEA and CYFRA21-1 for judging non-small cell lung cancer pathological type have some help.